Infigratinib for Treatment of FGFR3-RELATED Skeletal Diseases During Pregnancy
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 12,778,952 | Infigratinib for Treatment of FGFR3-RELATED Skeletal Diseases During Pregnancy In force · High confidence | Assistance Publique-Hôpitaux de Paris (Aphp) | In force | High confidence | ||
| Application 17/280,620 | Infigratinib for Treatment of FGFR3-RELATED Skeletal Diseases During Pregnancy Abandoned Abandoned Apr 8, 2024 | Université Paris Cité | Abandoned | Abandoned Apr 8, 2024 |
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Fondation Imagine.
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.